Sanofi, Google team up on diabetes; Lilly, Boehringer nab FDA approval for SGLT2 combo med; Allergan wraps Naurex deal;

@FiercePharma: ICYMI: Judge halts lawsuit blaming Purdue, Endo and others for epidemic of drug abuse. Article | Follow @FiercePharma

@EricPFierce: Majority of Mylan shareholders approve buyout of Perrigo, despite adamant opposition by its management. Press release | Follow @EricPFierce

@CarlyHFierce: 'No signal' of heart failure risk with Merck's Januvia, analysis confirms. Article | Follow @CarlyHFierce

> Sanofi ($SNY) inked a deal with Google's ($GOOG) newly launched life sciences division to work together on new treatment approaches, including digital-plus-drug approaches. Report

> Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's new diabetes combo med Synjardy--which combines the active ingredient in the SGLT2 drug Jardiance with metformin--won U.S. approval, becoming the third empagliflozin product blessed by the FDA. Release

> Allergan ($AGN) wrapped up its $560-million-plus deal for Naurex and its two antidepressants, which recently posted promising mid-stage data. Release

> Novartis' ($NVS) eye care division Alcon Laboratories, Johnson & Johnson ($JNJ) and Bausch & Lomb struggled to defend their pricing policies in a federal appeals court Thursday, with the judges repeatedly challenging the companies' arguments. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Updated $ABT's interest in $STJ w/ info from old article on their prior partnership. Neat to add context from 2012. Article | Follow @VarunSaxena2

@EmilyWFierce: $GOOG and $SNY are teaming up for #diabetes monitoring. More from the WSJ | Follow @EmilyWFierce

> Google pairs with Sanofi for diabetes monitoring collaboration. Story

> Precedent from Amarin's off-label promotion victory covers devices, too, especially those marketing a surrogate endpoint. Editor's Corner

> Philips debuts two new cardio products to European market at London conference. Article

Biotech News

@FierceBiotech: Alnylam, Medicines Co. say next-gen PCSK9 drug has blockbuster potential. Article | Follow @FierceBiotech

@JohnCFierce: Amicus bags PhIII rare disease drug in $847M Scioderm buyout. News | Follow @JohnCFierce

@DamianFierce: Missed the FDA biosimilar-naming thing because vacation, but I'm a big fan of the phrase "suffix devoid of meaning." More | Follow @DamianFierce

> Intercept wins priority review for OCA. Item

> Sanofi buys into Google's biotech future, pairing up in diabetes. Story

> Bayer takes its heart-failure drug into Phase III after a mid-stage success. Report

> Step 3: After an immunotherapy makeover, CytomX files $100M IPO. More

Animal Health News

> Denver cannabis seller teams with vet to launch pet wellness line. Item

> Cornell U spotlights veterinary profession on Nat Geo reality TV show. News

> Patterson shares fall on missed sales and earnings targets. More

> Young entrepreneur shows off veterinary product at White House Demo Day. Story

> Academic docs and biotechs partner with veterinarians to find cancer cures. Article

Biotech IT News

> Ginkgo Bioworks allies with Ajinomoto to expand into amino acid production. Item

> Venter's HLI nabs Millennium Health COO to oversee global expansion. Report

> Mytrus makes electronic informed consent breakthrough in U.K. Story

> How openFDA's 'crazy collision' of Silicon Valley and federal culture is reshaping the regulator. More

> UCL taps Elsevier resource to advance drug repurposing research. Article

Pharma Marketing News

> The 'Kardashian Effect' on pharma begs the question: Does social media influence drug requests? Story

> The need-to-know from ESC (so far): Merck, BMS, Pfizer and Sanofi. More

> Repatha vs. Praluent matchup has Amgen, Sanofi zeroing in on key details. Article

> Dutch pension fund dumps Mylan on worries about death penalty drug. Item

> Want to improve drug adherence, pharma? Get tracking. More

And Finally... Device maker Medtronic ($MDT) said it had identified genetic abnormalities associated with sudden cardiac death. Report